Shares of AC Immune SA (NASDAQ:ACIU) have earned an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy recommendation.

Analysts have set a twelve-month consensus target price of $23.00 for the company and are predicting that the company will post ($0.07) earnings per share for the current quarter, according to Zacks. Zacks has also given AC Immune SA an industry rank of 99 out of 265 based on the ratings given to related companies.

Several research firms recently commented on ACIU. Zacks Investment Research lowered AC Immune SA from a “hold” rating to a “sell” rating in a research report on Thursday, July 20th. Credit Suisse Group set a $18.00 price target on AC Immune SA and gave the stock a “buy” rating in a research report on Wednesday, July 19th.

ILLEGAL ACTIVITY WARNING: “AC Immune SA (ACIU) Given Consensus Recommendation of “Strong Buy” by Analysts” was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/08/08/ac-immune-sa-aciu-given-consensus-recommendation-of-strong-buy-by-analysts.html.

A number of institutional investors have recently added to or reduced their stakes in ACIU. Cohen Lawrence B bought a new position in AC Immune SA during the second quarter valued at approximately $297,000. Monashee Investment Management LLC raised its position in AC Immune SA by 74.7% in the first quarter. Monashee Investment Management LLC now owns 30,000 shares of the company’s stock valued at $311,000 after buying an additional 12,832 shares during the period. Finally, Victory Capital Management Inc. raised its position in AC Immune SA by 78.4% in the first quarter. Victory Capital Management Inc. now owns 26,757 shares of the company’s stock valued at $277,000 after buying an additional 11,757 shares during the period. 18.47% of the stock is currently owned by hedge funds and other institutional investors.

AC Immune SA (ACIU) traded up 2.43% during midday trading on Tuesday, hitting $7.58. 13,785 shares of the stock traded hands. AC Immune SA has a 52-week low of $6.66 and a 52-week high of $19.97. The stock has a 50-day moving average of $8.53 and a 200 day moving average of $10.19. The firm’s market cap is $431.47 million.

AC Immune SA (NASDAQ:ACIU) last released its quarterly earnings results on Thursday, May 11th. The company reported ($0.17) EPS for the quarter, hitting the consensus estimate of ($0.17). The company had revenue of $1.99 million for the quarter, compared to analyst estimates of $3.43 million. Equities analysts forecast that AC Immune SA will post ($0.57) EPS for the current year.

AC Immune SA Company Profile

AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.

Get a free copy of the Zacks research report on AC Immune SA (ACIU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AC Immune SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune SA and related companies with MarketBeat.com's FREE daily email newsletter.